Novel Therapeutic Approach for Parkinson Disease during REM Sleep
|Miguel Angel Pieroni1,2* and Pablo Gustavo Pieroni3|
|1Department of Neurology, Pablo Soria Hospital, San Martin 210- San Salvador de Jujuy, Argentina|
|2Department of Neurology, FIDES Sleep Center, Jujuy, Argentina|
|3Department of Cardiology, FIDES Sleep Center, Jujuy, Argentina|
|*Corresponding Author :||Miguel Angel Pieroni
Department of Neurology
Pablo Soria Hospital
San Martin 210- San Salvador de Jujuy, Argentina
E-mail: [email protected]
|Received: Feb 11, 2016; Accepted: Mar 08, 2016; Published: Mar 10, 2016|
|Citation: Pieroni MA, Pieroni PG (2016) Novel Therapeutic Approach for Parkinson Disease during REM Sleep. J Health Edu Res Dev 4:164. doi:10.4172/2380-5439.1000164|
|Copyright: © 2016 Pieroni MA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Study objectives: The physiological responses of an individual depend on preset limits. They must be able to adapt it to changing environmental conditions, modifying the thresholds. We propose a regulatory function of biological responses during REM sleep. Responses previously developed during wakefulness, are evaluated and regulated for integration into the repertoire of responses during sleep. The aims of this study were to evaluate the impact of the restoration of REM sleep in patients with Parkinson disease by stimulation of D2 receptors and to evaluate the symptomatic benefit of this approach.
Methods: Ten parkinsonian patients underwent a polysomnography study using nocturnal apomorphine subcutaneous administration at the beginning of each REM detected along all night recording.
Results: This therapeutic approach led to a significant benefit for patients in all of three UPDRS scores. The mean UPDRS III motor examination “On” scores (mean ± SD) were reduced by 9.4 ± 8.5 points (p<0.0001). For patients in the UPDRS II scores a total difference of 12 ± 4.22 to 5.2 ± 5.22 (p<0.0001) were observed; and in total UPDRS I the difference was of 5.2 points (p<0.0001), with a reduction from 8.4 ± 3.2 to 3.2 ± 3.1.
Conclusion: Sleep alteration can be improved by stimulation of D2 receptors. The symptomatic benefits obtained linked to the restoration of REM functions in patients with PD were significant.